OncoTargets and Therapy (Oct 2022)
PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far
Abstract
Tina Di Palma, Mariastella Zannini IEOS - Institute of Experimental Endocrinology and Oncology ‘G. Salvatore’, National Research Council, Napoli, 80131, ItalyCorrespondence: Mariastella Zannini, IEOS - Institute of Experimental Endocrinology and Oncology ‘G. Salvatore’, National Research Council, via S. Pansini 5, Napoli, 80131, Italy, Tel +39-081-5465530, Fax +39-081-2296674, Email [email protected]: The Fallopian tube epithelium harbors the origin cells for the majority of high-grade serous ovarian carcinomas (HGSCs), the most lethal form of gynecologic malignancies. PAX8 belongs to the paired-box gene family of transcription factors and it is a marker of the FTE secretory cell lineage. Its role has been investigated in migration, invasion, proliferation, cell survival, stem cell maintenance, angiogenesis and tumor growth. In this review, we focus on the pro-tumorigenic role of PAX8 in ovarian cancer; in this context, PAX8 possibly continues to exert its transcriptional activity on its physiological targets but may also function on newly available targets after the tumorigenic hits. Acquiring new insights into the different PAX8 mechanism(s) of action in the tumor microenvironment could uncover new viable therapeutic targets and thus improve the current treatment regimen.Keywords: PAX8, ovarian cancer, transcription factor, Fallopian tube, STICs
